Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2012

View Archived Issues

Mitsubishi Tanabe Pharma offers overview of second quarter 2012

Encouraging phase III results presented for Biocon's insulin biosimilar

Cubist Pharmaceuticals begins phase III program for CB-5945

European Commission denies marketing authorization for taliglucerase alfa

Phase I results reported for ICT-107 in glioblastoma multiforme

British and French group presents novel vaccines for AIDS

Qilu Pharmaceutical discloses novel EGFR inhibitors

Shanghai Allist Pharmaceutical patents new PI3K inhibitors

Novel tyrosine-protein kinase inhibitors prepared at Pharmascience

Phase II study of GS-7340 meets 24-week primary objective

Lundbeck prepares new antibodies for Alzheimer's disease

New CSF-1 receptor inhibitors divulged by Pharmascience

Sanofi presents pipeline highlights of third quarter 2012

Degarelix evaluated in women undergoing in vitro fertilization

Immune Response BioPharma publishes full results from phase III study of HIV vaccine

Vertex enters agreements for VX-135 combination studies

Lisdexamfetamine mesilate proves beneficial in cognitively impaired MS patients

FDA requests additional information in CRL for lixivaptan NDA

AlphaCore obtains EMA orphan drug designation for ACP-501

Aerie reports topline data from phase IIa studies of its ROCK inhibitors

Glybera gene therapy approved by the European Commission

Hutchison MediPharma begins phase I study of novel EGFR inhibitor

BAX B-01 shows promise in model of proliferative nephritis

Phase III trial of Adcetris in advanced Hodgkin's lymphoma begins

Keryx Biopharmaceuticals commences phase II study of Zerenex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...